Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Research Protocols

Date Submitted: May 20, 2026
Open Peer Review Period: May 21, 2026 - Jun 26, 2026
Date Accepted: Jul 30, 2026
(closed for review but you can still tweet)

The final, peer-reviewed published version of this preprint can be found here:

Memory B Cells and Antibody Responses to Vaccines in Infected Children (MARVIC) With Recurrent Infections: Protocol for a Prospective Observational Study

Jamaluddin J, Mohamad SM, Zainal Abidin MA, Mohamed Nashrudin KN, Osman M, Ismail IH

Memory B Cells and Antibody Responses to Vaccines in Infected Children (MARVIC) With Recurrent Infections: Protocol for a Prospective Observational Study

JMIR Res Protoc 2026;15:e101835

DOI: 10.2196/101835

PMID: 42867869

Observational Study of Children with Recurrent Infections: Protocol for the Memory B-Cells and Antibody Responses to Vaccines in Infected Children (MARVIC) Study

  • Jalilah Jamaluddin; 
  • Siti Mardhiana Mohamad; 
  • Mohd Azri Zainal Abidin; 
  • Khairoon Nisa Mohamed Nashrudin; 
  • Malina Osman; 
  • Intan Hakimah Ismail

ABSTRACT

Background:

Recurrent infections in children are a significant concern in paediatric practice, often prompting investigations into potential inborn errors of immunity (IEI), previously referred to as primary immunodeficiency diseases (PIDs). These infections, particularly those with sinopulmonary manifestations such as pneumonia, sinusitis, and otitis media, may suggest underlying humoral or B cell deficiencies, which are among the most common types of IEIs. Key laboratory tests for diagnosing these deficiencies include measurement of immunoglobulins (IgG, IgA, IgM) and IgG subclasses (IgG1, IgG2, IgG3, IgG4) levels, vaccine-specific antibody responses, and B lymphocyte enumeration. These tests assess both the quantity and functionality of humoral immunity, which is crucial for protection against various pathogens. Currently, reference intervals for these immunological parameters have not been well-defined in the Malaysian paediatric population.

Objective:

This study aims to investigate the humoral immune system among Malaysian children with recurrent infections and to establish reference values for humoral immunity.

Methods:

Blood samples will be analysed to determine levels of immunoglobulins and IgG subclasses using nephelometry, vaccine-specific antibody responses will be assessed through enzyme-linked immunosorbent assays (ELISA), and memory B cell profiles will be determined using flow cytometry.

Results:

The study, which received funding in 2024, is currently ongoing. Completion of data collection and statistical analysis is anticipated by December 2026.

Conclusions:

Comprehensive evaluation of the humoral immune profile in children with recurrent infections offers deeper insight into underlying immunological abnormalities and enhances clinicians’ accuracy in diagnosing immunodeficiency.


 Citation

Please cite as:

Jamaluddin J, Mohamad SM, Zainal Abidin MA, Mohamed Nashrudin KN, Osman M, Ismail IH

Memory B Cells and Antibody Responses to Vaccines in Infected Children (MARVIC) With Recurrent Infections: Protocol for a Prospective Observational Study

JMIR Res Protoc 2026;15:e101835

DOI: 10.2196/101835

PMID: 42867869

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.